REPORT HIGHLIGHTS
-
The total U.S. market for reproductive technologies and products is estimated to be $6.5 billion in 2004. In 2009, revenues will likely reach $9.8 billion, rising at an average annual growth rate (AAGR) of 8.6%.
-
Contraceptive products currently account for the highest amount of revenues and are expected to grow at an AAGR of 9.1% through the period.
-
Sexual dysfunction products are expected to show the highest annual growth at an average of 12.3% through 2009.
-
Few areas in medicine have posed so many social and ethical questions and attracted so much public attention as has assisted reproductive technology (ART) to manage infertility.
SUMMARY FIGURE
TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS’ SALES LEVELS, 2002-2009
($ MILLIONS)
Source: BCC, Inc.
REPORT SCOPE
INTRODUCTION
In each of the three major areas of infertility, contraception and sexual dysfunction, there is increasing interest and advancements. One of the most widely publicized, celebrated and, at the time, controversial medical landmarks in this area was the use of assisted reproductive technology (ART) to manage infertility. Recent developments in the field of ART have intensified the hopes and wishes of infertile people to resolve their infertility.
New developments in the area of contraception have stepped up the quest for easier, safer and more convenient contraception methods. There is no miracle drug or contraception method but scientists are pursuing several avenues of discovery to create better options for individuals.
Sexual dysfunction now is an acknowledged disorder in the eyes of the general public and the medical community. Prior to the introduction of Viagra™, the disorder was present but not acknowledged, and largely went untreated.
This BCC study presents a comprehensive, up-to-date look at the market for reproductive drugs and technologies. Markets are divided according to treatment type and indication. The products in some markets are mature, while those in other markets are just beginning to emerge. The competitive landscape is comprised of large, established pharmaceutical companies and many smaller developing companies. The reproductive health arena still is wide open in terms of competition because there still is a great need to provide products that are safe and effective.
SCOPE OF STUDY
The report contains:
- A review of male and female reproductive health
- An overview of standard pharmaceutical treatments, devices and technologies
- An analysis of market size in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception and sexual dysfunction with forecasts to 2009
- Market participants and current competitor market shares
- An investigation of pipeline products and technologies.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on extensive first hand interviews with primary executives, product managers, and clinical specialists in the area of reproductive health. Random surveying provided information about use of products and how products are obtained. Background information was obtained from various government and sources, medical journals, and trade magazines and interviews with doctors. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in reproductive drugs and technologies in healthcare. Interviews were also used to confirm and/or adjust market size and competitor market share estimates, as well as to formulate market projections.
All market data pertain to the U. S. market at the manufacturer's level. Data are expressed in current U. S. dollars. The base year is 2004; historical data are provided for 2002 and 2003 and forecast data are provided for 2009. Historical, base year and forecast data are provided for each market segment and subsegment. Market share information is provided for each market subsegment for the 2004 base year.
All average annual growth rates are estimated based on the compilation of data, which includes estimated prevalence of conditions, population growth, products in research and development, historical trends, patent expirations and generic competition.
ANALYST CREDENTIALS
Mary Anne Crandall has been publishing market research in the life sciences for more than 17 years. She holds a Master of Science Degree in psychology, and is the founder and CEO of Mountaintop Medical, LLC, a consulting firm in Oregon. She has taught at Southern Oregon University for more than 16 years, and before joining BCC's analytical team, she published with Frost & Sullivan, Theta Reports, FIND/SVP, MDI, FeedBack Research Services, Prognosis and Hall Enterprises. Ms. Crandall specializes in prescription pharmaceutical markets.
